Medela Potentia Distributes 2025 Dividend of Rp176.56 Billion, Check the Schedule
The Annual General Meeting of Shareholders (AGMS) of PT Medela Potentia Tbk (MDLA) has agreed on three main agendas: the distribution of cash dividends for the 2025 fiscal year, changes to the board of directors, and the company’s growth strategy for 2026.
The AGMS held today in Jakarta approved a cash dividend distribution of Rp176,561,595,000, equivalent to Rp12.6 per share. This decision reflects the company’s solid performance and consistent delivery of sustainable added value to shareholders.
Company Secretary Wimala Widjaja stated that this dividend distribution reflects the company’s commitment to consistently providing added value to shareholders since becoming a public company. In the previous year, the company distributed dividends at 40% of net profit, while for the 2025 fiscal year, it increased the payout ratio to 45% of net profit.
“The company maintains a regular dividend of 40% of net profit, while adding an extra dividend of 5%. The total dividend distributed reaches Rp12.6 per share, an increase of 28.5% compared to the previous year,” said Wimala, quoted from her statement on Tuesday, 12 May 2026.
In the AGMS, shareholders also approved the resignation of Krestijanto Pandji from his position as President Director. The company expressed appreciation for Krestijanto Pandji’s contributions to strengthening corporate governance, accelerating business transformation, and improving corporate performance as well as the company’s adaptability.
Subsequently, the AGMS appointed Juliwaty as the company’s President Director. Prior to serving as President Director of PT Medela Potentia Tbk, Juliwaty was President Director of PT Anugrah Argon Medica (AAM), a subsidiary of PT Medela Potentia Tbk, and has extensive experience in the healthcare industry. This change in the board of directors is expected to continue the company’s leadership while enhancing performance in facing healthcare industry dynamics.
This leadership transition is part of the company’s strategic steps to maintain performance continuity and strengthen long-term growth direction. “This leadership change is expected to further strengthen the organisational foundation and drive the acceleration of the company’s business strategy sustainably,” said Wimala.
In line with the growth strategy, the company continues to strengthen its business foundation through the development of national distribution infrastructure, including plans to inaugurate a new building and warehouse for the PT Anugrah Argon Medica branch in Medan. This step is part of efforts to increase the reach of pharmaceutical distribution services in western Indonesia.